See more : Escalon Medical Corp. (ESMC) Income Statement Analysis – Financial Results
Complete financial analysis of BioNxt Solutions Inc. (XPHYF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioNxt Solutions Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Spree Acquisition Corp. 1 Limited (SHAP-UN) Income Statement Analysis – Financial Results
- Kuangda Technology Group Co., Ltd. (002516.SZ) Income Statement Analysis – Financial Results
- Speed Rabbit Pizza SA (MLSRP.PA) Income Statement Analysis – Financial Results
- National Capital Bancorp, Inc. (NACB) Income Statement Analysis – Financial Results
- Global Blue Group Holding AG (GB) Income Statement Analysis – Financial Results
BioNxt Solutions Inc. (XPHYF)
About BioNxt Solutions Inc.
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
COVID Tests, THC Patches, Psychedelics: Xphyto Therapeutics Does it All
XPhyto Reports Successful Market Launch and Growing Demand for its 25-minute COVID-19 PCR Test COVID-ID Lab
XPhyto Launches First Commercial Biosensor for Oral Disease
XPhyto's Acquisition Target, 3a-Diagnostics, Reports Breakthrough Identification of COVID-19 Biosensor Candidates
XPhyto in transformative acquisition with 3a-diagnostics to enter hi-tech biosensor market and expand diagnostic product portfolio
XPhyto Signs Transformative Acquisition Agreement With 3a-Diagnostics, to Enter Hi-Tech Biosensor Market and Expand Its Diagnostic Product Portfolio
XPhyto Announces Advertising Agreement with Agora Internet Relations Corp.
XPhyto supplies 10 test centers in Berlin with its 25-minute COVID-19 PCR tests
XPhyto Supplies 10 Test Centers in Berlin with 25-minute COVID-19 PCR Test
XPhyto Therapeutics Corp. Featured in Syndicated Broadcast Covering Latest Progress Report on Mescaline Program for Psychedelic Therapies
Source: https://incomestatements.info
Category: Stock Reports